



The Computational Methods for Anticancer Drug Development

Guest Editor:

Dr. Liye He

Computational Systems
Medicine, University of Helsinki,
Helsinki, Finland

Deadline for manuscript
submissions:

25 September 2024

Message from the Guest Editor

Dear Colleagues,

Computational methods have become increasingly popular in anticancer drug development. The availability of data sets as well as advances in new ML technologies enable us to apply ML methods, such as for guiding the high-throughput screening and optimization as well as identifying new drug targets, predicting treatment responses, identifying new biomarkers, and repositioning approved drugs. We now still face challenges on how to interpret most DL methods due to their complex “black-boxes” nature. Since most existing methods utilize preclinical disease models, very limited solutions currently exist that can make more clinically actionable predictions using different types of data, such as clinical data. Furthermore, user-friendly toolboxes are still lacking for non-computational cancer researchers, meaning powerful computational models are unable to be used in their research. In this Special Issue, we mainly focus on novel and explainable computational methods as well as easy-to-use toolboxes to accelerate the process of developing personalized anticancer treatments.

Dr. Liye He
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)